Ian Smith
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Huober J, Hackman J, Dasappa L, Ciruelos E, Toral Pena J, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber R, Piccart-Gebhart M, Jouannaud C, Wildiers H, Lecocq C, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Láng I, Smith I, Boyle F, Xu B, Di Cosimo S. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer 2019; 118:169-177.
01.08.2019Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
01.08.2019Eur J Cancer 2019; 118:169-177
Huober Jens, Hackman John, Dasappa Lokanatha, Ciruelos Eva, Toral Pena Juan Carlos, Adamchuk Hryhoriy, Hickish Tamas, de la Pena Lorena, Jackisch Christian, Gelber Richard D, Piccart-Gebhart Martine, Jouannaud Christelle, Wildiers Hans, Lecocq Christophe, Holmes Eileen, Baselga José, de Azambuja Evandro, Untch Michael, Fumagalli Debora, Sarp Severine, Láng István, Smith Ian, Boyle Frances, Xu Binghe, Di Cosimo Serena
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study
Borgquist S, Regan M, Gelber R, Price K, Rabaglio M, Goldhirsch A, Coates A, Smith I, von Moos R, Ejlertsen B, Debled M, Láng I, Colleoni M, Garber J, Ahern T, Giobbie-Hurder A, Thürlimann B. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. J Clin Oncol 2017; 35:1179-1188.
13.02.2017Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study
13.02.2017J Clin Oncol 2017; 35:1179-1188
Borgquist Signe, Regan Meredith M, Gelber Richard D, Price Karen N, Rabaglio Manuela, Goldhirsch Aron, Coates Alan S, Smith Ian, von Moos Roger, Ejlertsen Bent, Debled Marc, Láng István, Colleoni Marco, Garber Judy E, Ahern Thomas P, Giobbie-Hurder Anita, Thürlimann Beat
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Chirgwin J, Colleoni M, Láng I, Neven P, Forbes J, Rabaglio M, Smith I, Goldhirsch A, Gelber R, Debled M, Ejlertsen B, Price K, Coates A, Giobbie-Hurder A, Thürlimann B. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. J Clin Oncol 2016; 34:2452-9.
23.05.2016Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
23.05.2016J Clin Oncol 2016; 34:2452-9
Chirgwin Jacquie H, Colleoni Marco, Láng István, Neven Patrick, Forbes John F, Rabaglio Manuela, Smith Ian, Goldhirsch Aron, Gelber Richard D, Debled Marc, Ejlertsen Bent, Price Karen N, Coates Alan S, Giobbie-Hurder Anita, Thürlimann Beat
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Regan M, BIG 1-98 Collaborative Group, Thürlimann B, Coates A, Gelber R, Price K, Rabaglio M, Wardley A, Láng I, Smith I, Forbes J, Mauriac L, Ejlertsen B, Goldhirsch A, Giobbie-Hurder A, Neven P, International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 2011; 12:1101-8.
20.10.2011Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
20.10.2011Lancet Oncol 2011; 12:1101-8
Regan Meredith M, BIG 1-98 Collaborative Group, Thürlimann Beat, Coates Alan S, Gelber Richard D, Price Karen N, Rabaglio Manuela, Wardley Andrew, Láng István, Smith Ian, Forbes John F, Mauriac Louis, Ejlertsen Bent, Goldhirsch Aron, Giobbie-Hurder Anita, Neven Patrick, International Breast Cancer Study Group (IBCSG)
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Chirgwin J, Coates A, Goldhirsch A, Regan M, Bonnefoi H, Ejlertsen B, Thürlimann B, Price K, Smith I, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Res Treat 2011; 131:295-306.
04.09.2011The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
04.09.2011Breast Cancer Res Treat 2011; 131:295-306
Chirgwin Jacquie, Coates Alan S, Goldhirsch Aron, Regan Meredith M, Bonnefoi Hervé, Ejlertsen Bent, Thürlimann Beat, Price Karen N, Smith Ian, Sun Zhuoxin, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Colleoni M, Coates A, Gelber R, Price K, Wardley A, Pienkowski T, Chirgwin J, Smith I, Láng I, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Regan M, Giobbie-Hurder A, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011; 29:1117-24.
14.02.2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
14.02.2011J Clin Oncol 2011; 29:1117-24
Colleoni Marco, Coates Alan S, Gelber Richard D, Price Karen N, Wardley Andrew, Pienkowski Tadeusz, Chirgwin Jacquie, Smith Ian, Láng István, Paridaens Robert, Forbes John F, Mauriac Louis, Mouridsen Henning, Thürlimann Beat, Regan Meredith M, Giobbie-Hurder Anita, Goldhirsch Aron
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
BIG 1-98 Collaborative Group, Gelber R, Regan M, Price K, Forbes J, Mauriac L, Smith I, Paridaens R, Thürlimann B, Goldhirsch A, Giobbie-Hurder A, Mouridsen H, Coates A. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. NEJM 2009; 361:766-76.
20.08.2009Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
20.08.2009NEJM 2009; 361:766-76
BIG 1-98 Collaborative Group, Gelber Richard D, Regan Meredith M, Price Karen N, Forbes John F, Mauriac Louis, Smith Ian, Paridaens Robert, Thürlimann Beat, Goldhirsch Aron, Giobbie-Hurder Anita, Mouridsen Henning, Coates Alan S
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
Mouridsen H, Price K, Smith I, Colleoni M, Gelber R, Paridaens R, Forbes J, Mauriac L, Thürlimann B, Sun Z, Castiglione-Gertsch M, Rabaglio M, Coates A, Keshaviah A, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. JCO 2007; 25:5715-22.
20.12.2007Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
20.12.2007JCO 2007; 25:5715-22
Mouridsen Henning, Price Karen N, Smith Ian, Colleoni Marco, Gelber Richard D, Paridaens Robert, Forbes John F, Mauriac Louis, Thürlimann Beat, Sun Zhuoxin, Castiglione-Gertsch Monica, Rabaglio Manuela, Coates Alan S, Keshaviah Aparna, Goldhirsch Aron
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
Coates A, Del Mastro L, Smith I, Chirgwin J, Nogaret J, Pienkowski T, Wardley A, Jakobsen E, Price K, Láng I, Colleoni M, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes J, Paridaens R, Castiglione-Gertsch M, Gelber R, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. JCO 2007; 25:486-92.
10.02.2007Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
10.02.2007JCO 2007; 25:486-92
Coates Alan S, Del Mastro Lucia, Smith Ian, Chirgwin Jacquie, Nogaret Jean-Marie, Pienkowski Tadeusz, Wardley Andrew, Jakobsen Erik H, Price Karen N, Láng István, Colleoni Marco, Keshaviah Aparna, Thürlimann Beat, Mouridsen Henning, Mauriac Louis, Forbes John F, Paridaens Robert, Castiglione-Gertsch Monica, Gelber Richard D, Goldhirsch Aron
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
Breast International Group (BIG) 1-98 Collaborative Group, Price K, Wardly A, Wardley A, Smith I, Rabaglio M, Gelber R, Castiglione-Gertsch M, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Coates A, Keshaviah A, Thürlimann B, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. NEJM 2005; 353:2747-57.
29.12.2005A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
29.12.2005NEJM 2005; 353:2747-57
Breast International Group (BIG) 1-98 Collaborative Group, Price Karen N, Wardly Andrew, Wardley Andrew, Smith Ian, Rabaglio Manuela, Gelber Richard D, Castiglione-Gertsch Monica, Paridaens Robert, Forbes John F, Mauriac Louis, Mouridsen Henning, Coates Alan S, Keshaviah Aparna, Thürlimann Beat, Goldhirsch Aron